Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; Department of Geriatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Clin Biochem. 2024 May;127-128:110766. doi: 10.1016/j.clinbiochem.2024.110766. Epub 2024 Apr 26.
Sirtuin 7 (SIRT7), as a nicotinamide adenine dinucleotide-dependent protein/histone deacetylase, has been implicated in the pathogenesis of cardiovascular diseases. However, whether SIRT7 is related to hypertension remains largely unclear. Thus, this study aims to explore the effects and correlation between SIRT7 and hypertension.
A total of 72 patients with essential hypertension and 82 controls with non-hypertension were recruited at Beijing Tongren Hospital Affiliated with Capital Medical University from July 2022 to June 2023. Plasma SIRT7 expression was measured using enzyme-linked immunosorbent assay analysis. Clinical baseline characteristics, laboratory measurements, echocardiographic data, and medical therapy were collected.
Plasma levels of SIRT7 were lower in hypertensive patients compared with non-hypertensive patients [0.97 (0.58-1.30) vs. 1.24 (0.99-1.46) ng/mL, P < 0.001, respectively]. Furthermore, compared with the low SIRT7 group, there were lower levels of systolic blood pressure, hyperlipidemia, and the ultrasonic electrocardiogram parameters left ventricular end-diastolic diameter and left atrial in diastole in the high SIRT7 group (P < 0.05, respectively). More importantly, multivariate logistic regression analyses indicated that plasma SIRT7 was a predictor of hypertension [OR: 0.06, 95 % CI (0.02-0.19), P < 0.001]. Receiver operating characteristics curve analysis revealed that the optimal cutoff value for plasma SIRT7 levels in detecting hypertension was determined as 0.85 ng/mL with a sensitivity of 73.6 % and a specificity of 89.0 %. The area under the curve for SIRT7 was 0.821 (95 % CI, 0.751-0.878; P < 0.001).
Plasma levels of SIRT7 are decreased in patients with essential hypertension, implying its potential as a biomarker for diagnosing essential hypertension..
Sirtuin 7（SIRT7）作为一种烟酰胺腺嘌呤二核苷酸依赖性蛋白/组蛋白去乙酰化酶，与心血管疾病的发病机制有关。然而，SIRT7 是否与高血压有关仍不清楚。因此，本研究旨在探讨 SIRT7 与高血压之间的关系。
2022 年 7 月至 2023 年 6 月，首都医科大学附属北京同仁医院共纳入 72 例原发性高血压患者和 82 例非高血压对照者。采用酶联免疫吸附试验分析测定血浆 SIRT7 表达。收集临床基线特征、实验室检查、超声心动图数据和药物治疗情况。
高血压患者的血浆 SIRT7 水平低于非高血压患者[0.97（0.58-1.30）比 1.24（0.99-1.46）ng/mL，P<0.001]。此外，与低 SIRT7 组相比，高 SIRT7 组收缩压、血脂异常和超声心动图参数左心室舒张末期直径和舒张期左心房内径较低（P<0.05）。更重要的是，多元逻辑回归分析表明，血浆 SIRT7 是高血压的预测因子[比值比：0.06，95%置信区间（0.02-0.19），P<0.001]。受试者工作特征曲线分析显示，血浆 SIRT7 水平检测高血压的最佳截断值为 0.85ng/mL，敏感性为 73.6%，特异性为 89.0%。SIRT7 的曲线下面积为 0.821（95%置信区间，0.751-0.878；P<0.001）。
原发性高血压患者的血浆 SIRT7 水平降低，提示其可能成为诊断原发性高血压的生物标志物。
